# PUBLIC SUMMARY DOCUMENT

**Product:** Omnigon Flexima

**Applicant:** Omnigon

**Date of Meeting:** 20 April 2021

## Proposed Variation on the Stoma Appliance Scheme

The applicant, Omnigon, sought a change in the product description of two variants to the current listing of Omnigon Flexima (SAS Code 9926K) in subgroup 1(b), of the Stoma Appliance Scheme (the Scheme) Schedule. The product, including 10 variants, is currently listed at a unit price of $2.735, with a maximum annual quantity of 90 units.

## Variants to be added

The applicant requested a change in the product description of company code 44015 and 44115.

## Background

This product was first listed on the SAS Schedule in 1 April 2011.

## Clinical Place for the Product

Not Applicable.

### Financial Analysis

The change in product description of two variants is recommended on a cost-minimisation basis compared to products currently listed in subgroup 1(b) of the SAS Schedule. It is therefore, unlikely that there would be any budgetary impact for the SAS as a consequence of changing the product description of two variants.

## SPAP Recommendation

The Panel recommended the change of product description of two variants to the current product range for Omnigon Flexima (SAS Code 9926K) listed in subgroup 1(b), of the SAS Schedule at the unit price of $2.735, with a maximum monthly quantity of 90 units.

## Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context.
A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government.
All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Omnigon agrees with the SPAP’s recommendation.